

Figure 1. Flow of patients in this study. HCC, hepatocellular carcinoma.

may determine the patient's prognosis. Exclusion criteria were as follows: (i) tumor not visualized by ultrasonography/not accessible percutaneously; (ii) total bilirubin level  $\geq 3.0$  mg/dl; (iii) platelet count  $< 50 \times 10^9/l$  or prothrombin activity  $< 50\%$ ; (iv) refractory ascites; (v) enterobiliary reflux; and (vi) adhesion between the tumor and the gastrointestinal tract. In general, we performed RFA on Child-Pugh class A or B patients, a single tumor  $\leq 5$  cm in diameter, or three or fewer tumors  $\leq 3$  cm in diameter. In cases beyond these conditions, we performed RFA on patients who were likely to benefit from this procedure for possible cure or prolongation of life. No patients were excluded solely on account of tumor location (18). Informed consent was obtained from each patient. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki and approved by the institutional review board (Registration ID: P98C05-11Y).

### Patients

In this cohort study, we analyzed a prospectively collected computerized database. Between February 1999 and December 2009, 2,825 HCC patients were admitted once or more to the Department of Gastroenterology, the University of Tokyo (Figure 1). At initial hospitalization, 1,485 had primary HCC and the remaining 1,340 had recurrent HCC. In the recurrent HCC patients, primary HCC had previously been treated by therapies other than RFA.

Of the 1,485 primary HCC patients, 1,294 (87.1%) underwent percutaneous ablation as the initial treatment, including RFA. The remaining 191 patients underwent other therapies: hepatic resection, 29 patients with good liver function and who consented to an operation; transarterial chemoembolization, 149 with multinodular or large tumors that could not be treated by ablation therapies; systemic chemotherapy, three with extrahepatic metastasis; and only supportive care, 10 with decompensated cirrhosis or poor general condition.

Of the 1,294 patients treated by percutaneous ablation, 1,170 underwent RFA and the other 124 underwent ethanol injection. The choice of therapy was made as follows: between April 1999 and January 2001, 232 patients with three or fewer tumors, each  $\leq 3$  cm in diameter, and Child-Pugh class A or B liver function were entered into a randomized controlled trial to compare RFA with ethanol injection (6). Patients outside these inclusion criteria were mostly treated by RFA. After this trial, RFA was generally the treatment of choice, and ethanol injection was administered only to those considered unsuitable for RFA; ethanol injection was administered to those with either enterobiliary reflux or adhesion of the tumor to the gastrointestinal tract.

HCC was diagnosed based on typical imaging findings; that is, early-phase enhancement and late-phase contrast washout on dynamic computed tomography (CT) (19). HCC diagnosis was also confirmed by biopsy in 1,078 (92.1%) of the 1,170 patients with RFA-treated primary HCC. A total of 998 (85.3%) were diagnosed as having liver cirrhosis.

In general, transarterial chemoembolization was combined with RFA in patients with either  $\geq 4$  tumors or those with even one tumor  $> 3.0$  cm in diameter, although indication criteria of this combination had changed over time. The combination of transarterial chemoembolization with RFA was performed in 324 primary HCC patients.

### Treatment methods

RFA was performed on an inpatient basis. Preoperative planning including evaluation of all imaging studies, and careful ultrasound examination was performed to identify the tumors and determine the access routes.

The procedure was performed according to an institutional protocol and in the presence of three physicians. One physician inserted the electrode under ultrasound guidance while another assisted the procedure; at least one had 8-year or longer experience of percutaneous ablation therapies. The remaining physician was responsible for the ultrasound machine and data recording. Video recording was performed occasionally to improve and standardize the procedure.

The precise techniques of RFA are described elsewhere (6). Briefly, all RFA procedures were performed percutaneously under ultrasound guidance (Power Vision 8000, Aplio XV or Aplio XG; Toshiba, Tokyo, Japan). We used artificial pleural effusion (20) or artificial ascites (21) for tumors, which were in the hepatic dome or adjacent to the gastrointestinal tract. After administration of sedatives and local anesthesia, a 17-gauge cooled-tip electrode (Cool-Tip; RF Ablation System, Covidien, Boulder, Colombia, CO) was inserted. Radiofrequency energy was delivered for 6–12 min for each application. For large tumors, the electrode was repeatedly inserted into different sites, such that the entire tumor could be enveloped by assumed necrotic volumes. Following the procedure, the patient remained in bed until the next morning.

A CT scan with a 5-mm section thickness was performed 1–3 days after RFA to evaluate technique effectiveness (22). Complete ablation was defined as hypoattenuation of the entire tumor. We intended to ablate not only the tumor but also some of the liver

parenchyma surrounding it. When we suspected that unablated tumor portions remained, the procedure was repeated. We did not predefine the procedure number in a treatment: treatment was generally continued until CT imaging demonstrated necrosis of the entire tumor.

#### Follow-up

To detect recurrence at an early stage, serum  $\alpha$ -fetoprotein (AFP), lectin-reactive AFP (AFP-L3), and des- $\gamma$ -carboxy-prothrombin (DCP) levels were measured monthly, and CT and ultrasonography were performed every 4 months. Local tumor progression was defined as the appearance of viable cancer tissue touching the initially treated tumor (22) and distant recurrence as the emergence of one or several tumor(s) separate from the primary site. Chest CT or bone scintigraphy was performed if extrahepatic recurrence was suspected. RFA was used for recurrence if the patient still met the indication criteria. If multiple recurrences were not treatable with RFA, transarterial chemoembolization was generally performed.

#### Statistical analysis

This is a report of a consecutive case series: all RFA treatments performed on primary HCC patients at the Department of Gastroenterology, University of Tokyo between February 1999 and December 2009 were included and none was excluded. Data are presented as mean  $\pm$  s.d. for quantitative variables, and as absolute frequencies for qualitative variables.

A "procedure" was defined as a single intervention episode comprising one or more ablation performed on one or more tumors and a "treatment" as the completed effort to ablate one or more tumors. A treatment comprised one or more procedures (22).

"Technique effectiveness" rate was defined as the percentage of successfully eradicated macroscopic tumors, as evidenced by CT scan 1–3 days after the last procedure (22).

Overall survival was calculated in the 1,170 primary HCC patients. Survival curves were generated by the Kaplan–Meier method. In addition to overall survival, some subgroup analyses were performed with clinical characteristics including tumor size, tumor number, and liver function. Recurrence was evaluated in 1,138 of the 1,170 primary HCC patients; the remaining 32 patients were excluded from the recurrence analysis because some small tumors had been left untreated by RFA on account of detection failure by ultrasonography. Recurrence rates were calculated by the Gaynor's method (23). All time estimates were made from the date of the first RFA. The follow-up was finalized at either death or the last visit to the outpatient clinic before 31 December 2009. Transplanted patients were censored from this study at the date of transplantation.

The prognostic relevance of 19 baseline variables (Table 1), the combination of transcatheter arterial chemoembolization (TACE) with RFA, HCC recurrence, and the number of RFA sessions to survival was analyzed by univariate and multivariate Cox proportional hazards regression models. The prognostic relevance of 19 baseline variables (Table 1), the combination of TACE with RFA, and the number of RFA sessions to local tumor progression and

distant recurrence was also analyzed by univariate and multivariate models. All variables with a  $P$  value  $< 0.05$  by univariate comparison were subjected to multivariate analysis. Some continuous variables in which log-linearity could not be assumed were transformed into categorical variables. In multivariate analysis, we evaluated two models that contained either Child-Pugh class or its components to avoid multicollinearity. A stepwise variable selection was performed with Akaike Information Criteria in multivariate analysis. The results of multivariate analyses were presented as a hazard ratio with corresponding 95% confidence interval (CI), with  $P$  values from the Wald test. All significance tests were two-tailed, and differences with a  $P$  value  $< 0.05$  were considered statistically significant.

Complications were defined according to the guidelines of the Society of Interventional Radiology (24).

## RESULTS

### Antitumor effect

We performed a total of 2,982 RFA treatments for the 1,170 primary HCC patients, comprising 4,514 procedures. Thus, procedure number per treatment was  $1.52 \pm 0.78$ . Many patients undergoing RFA for treatment of primary HCC received iterative RFA treatments for recurrence. A total of 485 patients underwent RFA treatment once, 247 twice, 177 thrice, 94 four times, 70 five times, 35 six times, 23 seven times, 14 eight times, 7 nine times, 7 ten times, 6 eleven times, 2 twelve times, 2 thirteen times, and 1 fourteen times.

Technique effectiveness rate was 99.4% (2,964/2,982 treatments). It was similar between the initial RFA treatments and the other RFA treatments for recurrence ( $P = 0.98$ ). Complete ablation of the tumor was achieved in 1,163 (99.4%) of the 1,170 initial treatments and in 1,801 (99.4%) of the 1,812 other RFA treatments. However, technique effectiveness rate significantly differed with tumor size ( $P = 0.023$ ). No apparent viable portions remained in the treated tumor in 1,642 (99.6%) of 1,648 treatments for tumors  $\leq 2.0$  cm in diameter, in 923 (99.2%) of 930 treatments for tumors 2.1–3.0 cm, in 356 (98.9%) of 360 treatments for tumors 3.1–5.0 cm, and in 43 (97.7%) of 44 treatments for tumors  $> 5.0$  cm. Final CT imaging demonstrated residual cancer tissue in the remaining 18 treatments. We decided against performing additional procedures, because liver failure rather than HCC seemed to determine the prognosis in 10 treatments, and because additional RFA would have caused complications on account of poor visualization or inaccessibility in the other eight treatments.

### Survival


The 19 baseline clinical characteristics of the 1,170 patients who underwent RFA for treatment of primary HCC are shown in Table 1. A total of 269 patients (23.0%) were  $> 75$  years old. In all, 422 patients had tumors  $\leq 2.0$  cm in diameter, 467 had tumors 2.1–3.0 cm, 246 had tumors 3.1–5.0 cm, and 35 had tumors  $> 5.0$  cm; 685 patients had 1 tumor, 395 had 2 or 3 tumors, and 90 had  $\geq 4$  tumors.

As of December 2009 (with a median follow-up of 38.2 months), 692 patients (59.1%) remained alive, 39 (3.3%) were lost to

**Table 1.** Baseline characteristics of the 1,170 patients undergoing radiofrequency ablation for primary hepatocellular carcinoma

Variable	
Age (years)	68.3±8.6
Males, n (%)	751 (64.1)
<b>Viral infection</b>	
HBs-Ag-positive, n (%)	127 (10.9)
Anti-HCV-positive, n (%)	870 (74.4)
Both positive, n (%)	13 (1.1)
Both negative, n (%)	159 (13.6)
Alcohol consumption >80g/d	170 (14.5)
Ascites, n (%)	117 (10.0)
Encephalopathy, n (%)	24 (2.1)
Albumin (g/dl)	3.65±0.47
Total bilirubin (mg/dl)	0.95±0.49
Prothrombin time (%)	79.6±14.1
Platelet count (×10 <sup>4</sup> /mm <sup>3</sup> )	11.9±5.6
AST (IU/l)	61.5±35.9
ALT (IU/l)	57.3±40.8
<b>Child-Pugh class, n (%)</b>	
A	868 (74.2)
B	291 (24.9)
C	11 (0.9)
Tumor size (cm)	2.54±1.04
Tumor number	1.8±1.2
<b>Serum AFP (ng/dl), n (%)</b>	
≤100	928 (793)
101–400	146 (12.5)
>400	96 (8.2)
<b>Serum DCP (mAU/ml), n (%)<sup>a</sup></b>	
≤100	964 (83.1)
101–400	126 (10.9)
>400	70 (6.0)
<b>Serum AFP-L3 (%), n (%)</b>	
≤15	1,015 (86.8)
15.1–40	74 (6.3)
>40	81 (6.9)

AFP, α-fetoprotein; AFP-L3, lectin-reactive α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCP, des-γ-carboxy-prothrombin; HCV, hepatitis C virus.  
Data are expressed as mean±s.d.  
<sup>a</sup>Serum DCP level could not be measured in 10 patients because they were being administered warfarin.

**Figure 2.** Overall survival in 1,170 primary hepatocellular carcinoma patients who underwent radiofrequency ablation.

follow-up, and 439 (37.5%) had died. Of the 1,170 patients, two were transplanted. The number of 5-, 7-, and 10-year survivors was 325, 131, and 16, respectively. The cause of death was HCC in 245 patients (55.8%), liver failure in 89 (20.3%), upper gastrointestinal bleeding in 11 (2.5%), complications related to the procedure in 3 (0.7%), liver-unrelated diseases in 81 (18.5%), and undetermined in 10 (2.3%).

The 1-, 3-, 5-, 7-, and 10-year survival rates of all 1,170 primary HCC patients were 96.6% (95% CI: 95.5–97.7%), 80.5% (95% CI: 78.0–83.1%), 60.2% (95% CI: 56.7–63.9%), 45.1% (95% CI: 40.9–49.6%), and 27.3% (95% CI: 21.5–34.7%), respectively (Figure 2; Table 2). Survival rates differed significantly with tumor size ( $P<0.0001$ ), tumor number ( $P=0.0003$ ), and Child-Pugh class ( $P<0.0001$ ). In the Child-Pugh class A or B patients with a single tumor  $\leq 5$  cm in diameter, or three or fewer tumors  $\leq 3$  cm in diameter, the 5-year survival rate was 63.8% (95% CI: 59.9–67.9%), while in those outside these criteria, it was 46.4% (95% CI: 39.4–54.8%).

Univariate analysis showed 19 of the 22 variables relevant to survival. In multivariate analysis that contained Child-Pugh class but not its components, a model that contained age, antibody to hepatitis C virus (anti-HCV), Child-Pugh class, tumor size, tumor number, serum DCP level, and serum AFP-L3 level was selected (Table 3). The other model that contained the components of Child-Pugh class is shown in Supplementary Table online.

### Recurrence

Recurrence developed in 741 patients. Local tumor progression alone was found in 25, local tumor progression with distant recurrence was found in 9, and distant recurrence alone was found in the other 707 patients. Of these 707 patients, 13 had the first recurrence in extrahepatic sites: 7 had lymph node metastasis, 3 had peritoneal seeding, 1 had lung metastasis, 1 had bone metastasis, and the remainder had both peritoneal seeding and lung metastasis. No recurrence developed in the remaining 397 patients.

Of the 741 patients, the first recurrence was treated by iterative RFA in 659 (88.9%), transarterial chemoembolization in 69 (9.3%), systemic chemotherapy in 4 (0.5%), surgical resection in 3 (0.4%), radiation therapy in 2 (0.3%), and supportive care in 4 (0.5%).

**Table 2.** Survival of patients undergoing radiofrequency ablation, based on tumor number, tumor size, and Child-Pugh class

Grading	n	Survival (%)					Median (years)	P value
		1-Year	3-Year	5-Year	7-Year	10-Year		
Overall survival	1,170	96.6	80.5	60.2	45.1	27.3	6.4	—
<i>Tumor number</i>								
Solitary	685	97.2	82.6	64.6	50.5	32.0	7.0	0.0003
2-3	395	95.7	77.9	54.4	39.4	19.9	5.6	
≥4	90	96.5	76.4	53.6	30.1	17.6	5.3	
<i>Tumor size</i>								
≤3cm	889	97.2	83.8	65.1	47.3	30.7	6.7	<0.0001
>3cm	281	94.8	71.0	46.5	38.0	18.6	4.6	
<i>Child-Pugh class</i>								
A	868	98.0	86.0	65.9	50.2	30.1	7.0	<0.0001
B	291	93.2	66.4	46.5	32.4	20.6	4.6	
C	11	81.8	58.4	23.4	23.4	—	3.1	
<i>Combination of tumor number, tumor size, and Child-Pugh class</i>								
Solitary, ≤3cm	534	97.6	84.7	68.0	51.4	34.3	7.1	—
Solitary, ≤3cm, Child-Pugh A	401	98.7	90.1	74.0	57.4	41.3	8.2	—
1-3 Tumors, ≤3cm	822	97.1	83.7	65.2	48.8	32.5	6.9	—
Solitary, ≤5cm, or 1-3 tumors, ≤3cm	947	97.2	82.8	63.8	48.8	30.6	6.9	—
<i>Child-Pugh A/B</i>								
Satisfied the indication criteria of surgical resection proposed in the BCLC protocol <sup>a</sup>	237	98.6	90.5	75.9	61.1	38.1	8.7	—

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.

<sup>a</sup>Child-Pugh class A with a normal level of bilirubin, no significant portal hypertension, and a single HCC.

The 1-, 3-, 5-, 7-, and 10-year rates of local tumor progression with or without distant recurrence were 1.4% (95% CI: 0.7–2.1%), 3.2% (95% CI: 2.1–4.3%), 3.2% (95% CI: 2.1–4.3%), 3.2% (95% CI: 2.1–4.3%), and 3.2% (95% CI: 2.1–4.3%), respectively (Figure 3). Univariate analysis demonstrated that prothrombin time and serum AFP, DCP, and AFP-L3 levels were correlated to local tumor progression, whereas multivariate analysis showed that serum DCP level alone was significantly correlated. Tumor size was not correlated to local tumor progression.

The 1-, 3-, 5-, 7-, and 10-year rates of distant recurrence without local tumor progression were 25.6% (95% CI: 23.0–28.2%), 63.3% (95% CI: 60.2–66.4%), 74.8% (95% CI: 71.8–77.8%), 78.1% (95% CI: 75.1–81.2%), and 80.8% (95% CI: 77.4–84.3%), respectively. Univariate analysis demonstrated 14 variables relevant to distant recurrence, whereas multivariate analysis showed that anti-HCV, Child-Pugh class, platelet count, tumor size, tumor number, serum AFP level, and serum DCP level were significantly related to distant recurrence (Table 3).

#### Complications

A total of 67 complications were encountered (Table 4). The incidence rates of complications per treatment and per procedure were 2.2% (67/2,982) and 1.5% (67/4,514), respectively. One patient

died of hepatic failure on account of massive hepatic infarction 7 days after the last RFA procedure. He had undergone 12 RFA treatments in 8 years. The treatment mortality rate was 0.03%.

#### DISCUSSION

This study describes our 10-year clinical experience with RFA at a high-volume center. We performed the 2,982 RFA treatments on a total of the 1,170 primary HCC patients, showing that RFA has a high antitumor effect. Tumors were judged to have been completely ablated by final CT imaging in 99.4% of the treatments. Complete response was achieved not only in the first RFA but also in iterative RFA for recurrence. Although complete response rate differed with tumor size, there was not a sharp drop-off in effectiveness. The complete response rate may be higher in this study than others probably because we generally repeated the procedure until CT imaging demonstrated complete tumor necrosis, whereas many other studies limited the procedure number of RFA to 2–3 (11,13,15). Complete ablation of tumors has been reported to be related to improved survival (25). There were the 18 treatments in which we did not perform additional RFA for residual cancer tissue. In those treatments, usefulness of RFA had been unclear at the initial session because of liver dysfunction or tumor burden.


**Table 3. Multivariate analysis of variables relevant to survival, local tumor progression, and distant recurrence**

Variable	Multivariate analysis Hazard ratio (95% CI)	P value
<b>Survival</b>		
Age (per year)	1.03 (1.02–1.04)	<0.0001
Anti-HCV-positive	1.34 (1.03–1.76)	0.03
Child-Pugh class		
A	1	
B or C	2.08 (1.69–2.56)	<0.0001
Tumor size (cm)		
≤2.0	1	
2.1–3.0	1.40 (1.10–1.80)	0.007
3.1–5.0	1.80 (1.37–2.38)	<0.0001
>5.0	1.50 (0.90–2.49)	0.12
Tumor number		
Solitary	1	
2–3	1.28 (1.04–1.59)	0.02
≥4	1.58 (1.13–2.21)	0.008
Serum DCP (mAU/ml)		
≤100	1	
101–400	1.22 (0.88–1.69)	0.24
>400	1.66 (1.14–2.42)	0.008
Serum AFP-L3 (%)		
≤15	1	
>15	1.45 (1.11–1.91)	0.008
<b>Local tumor progression</b>		
Serum DCP (mAU/ml)		
≤100	1	
101–400	2.51 (1.02–6.20)	0.05
>400	6.52 (2.63–16.1)	<0.0001
<b>Distant recurrence</b>		
Anti-HCV-positive	1.44 (1.19–1.75)	0.0002
Child-Pugh class		
A	1	
B or C	1.23 (1.03–1.45)	0.02
Platelet count (/l)		
>10 <sup>11</sup>	1	
≤10 <sup>11</sup>	1.36 (1.12–1.64)	0.002
Tumor size (cm)		
≤2.0	1	
2.1–3.0	1.30 (1.10–1.55)	0.003
3.1–5.0	1.29 (1.05–1.60)	0.02
>5.0	1.25 (0.75–2.08)	0.4

**Table 3. Continued**

Variable	Multivariate analysis Hazard ratio (95% CI)	P value
Tumor number		
Solitary	1	
2–3	1.36 (1.16–1.59)	0.0002
≥4	2.02 (1.53–2.66)	<0.0001
Serum AFP (ng/dl)		
≤100	1	
101–400	1.15 (0.92–1.44)	0.22
>400	1.36 (1.03–1.81)	0.03
Serum DCP (mAU/ml)		
≤100	1	
101–400	1.19 (0.92–1.54)	0.19
>400	1.72 (1.22–2.42)	0.002

AFP, α-fetoprotein; CI, confidence interval; DCP, des-γ-carboxy-prothrombin; HCV, hepatitis C virus.



**Figure 3.** Local tumor progression and distant recurrence in patients who underwent radiofrequency ablation.

This study shows that RFA could achieve long-term survival for as long as 10 years. Sixteen patients treated by RFA survived for >10 years. The variables relevant to survival were similar to those found in previous studies on ethanol injection (26,27), RFA, hepatic resection (28), and transarterial chemoembolization (29). Both liver function and tumor-related factors were associated with survival. In addition, age and anti-HCV were relevant to survival in this study. Age was among the prognostic factors, probably because 23.0% of the patients were >75 years old, which resulted in a higher percentage (18.5%) of liver-unrelated deaths in this study compared with others. Anti-HCV was among the prognostic factors, probably because anti-HCV-positive patients developed distant recurrence more frequently.

HCC frequently recurred after RFA; most recurrences were, however, not local tumor progression but distant recurrence. Frequent recurrence is not specific to RFA. After hepatic resection, the

**Table 4. Complications in 2,982 treatments of radiofrequency ablation for hepatocellular carcinoma**

Complication	No. of complications
Neoplastic seeding	24
Liver abscess	6
Hemoperitoneum	12
Hemothorax	5
Symptomatic pleural effusion	1
Massive hepatic infarction	6
Gastrointestinal perforation or penetration	5
Hemobilia	2
Skin burn	1
Pneumothorax	3
Gallbladder injury	1
Cerebral infarction	1

tumor recurrence rate exceeds 70% at 5 years (30,31). In this study, periodic follow-up detected most recurrences at limited stage. RFA was performed again for first recurrence in almost 90% of cases, although multimodal treatments were used in a long-term follow-up. On the other hand, repeat resection rate for first recurrence has been reported to range from 10.4 to 30.6% (31,32). Because RFA is less invasive than hepatic resection, iterative RFA can be performed for recurrence more easily.

Local tumor progression was found less frequently in this study than in other studies, having been reported to be around 10% at 3 years following RFA (13,14). Furthermore, different from the findings in previous reports (33,34), tumor size was not related to local tumor progression in this study. These differences are probably because we repeated RFA until we considered we had ablated not only the tumor itself but also some of the liver tissue surrounding it. Furthermore, to avoid local tumor progression, we were more cautious in the treatment of larger tumors when deciding whether sufficient ablation had been performed. Only serum DCP level was significantly related to local tumor progression in this study. Elevated serum DCP level may be related to the malignant potential of HCC such as the development of portal venous invasion (35).

The frequency of distant recurrence in this study was similar to that reported in other studies (13). Among the variables significantly related to distant recurrence, tumor size, tumor number, serum AFP level, and serum DCP level were probably related to micrometastasis, which had not been detected by imaging modalities before the treatment, while anti-HCV, Child-Pugh class, and platelet count were related to metachronous multicentric carcinogenesis, which developed based on underlying chronic liver disease.

From the viewpoint of survival and distant recurrence, patients with 2.1–5.0 cm tumors had significantly worse outcomes than those with  $\leq 2.0$  cm tumors while those with tumors  $> 5.0$  cm did not have worse rates than those with tumors  $\leq 2$  cm. This is probably

because the number of patients with tumors  $> 5.0$  cm ( $n = 35$ ) were not large enough for the difference to be statistically significant. Another possibility is selection bias. It is possible that patient with tumors  $> 5.0$  cm who underwent RFA had more favorable conditions for survival and distant recurrence except tumor size than those with 2.1–5.0 cm tumors.

In this study, 324 of the 1,170 patients were treated with combination of TACE and RFA at the initial treatment. Thus, we evaluated the combination as a possible variable that influences survival or recurrence. Univariate analysis demonstrated that the combined therapy was significantly correlated to overall survival, whereas multivariate analysis did not show the relationship. TACE was generally combined with RFA in patients with either  $\geq 4$  tumors or those with even one tumor  $> 3.0$  cm in diameter. This is why the correlation was significant in univariate analysis, while it was not in multivariable model in which the effect of other risk factors, such as tumor number and tumor size were adjusted. The combination of TACE and RFA was not significantly related to either local tumor progression or distant recurrence.

RFA was a safe procedure. Although many patients treated by RFA in this study were at high risk for surgical treatment because of advanced cirrhosis or other comorbidities, complications occurred in only 2.2% of the treatments. Other investigators have also reported low complication rates of 0–6.1% (11,13–16). For hepatic resection, morbidity rates of 38–47% have been reported even in recent studies (36–38).

To date, percutaneous ethanol injection has been considered the standard in ablation (5). However, randomized controlled trials have demonstrated the superiority of RFA (6–9), with RFA now largely replacing ethanol injection. We have also shifted from ethanol injection to RFA (10). At our department, RFA is currently the first option and ethanol injection is performed only on patients on whom RFA cannot be performed safely because of either entero-biliary reflux, adhesion between the tumor and the gastrointestinal tract, or other reasons.

Surgical resection has been considered the treatment of choice for HCC. Our first option for resectable HCC was also surgery. However, most patients who came to our department visited us because they did not want surgical resection. Thus, many patients in this study underwent RFA not because of unresectable tumor but because of refusal of surgery. Those who preferred surgery would have directly gone to the surgical department that has extensive experience in hepatic resection (38).

It is not easy to compare outcomes between RFA and surgical resection; the indications are different between the two treatments. Furthermore, indications for each treatment are different from institution to institution. Thus, a case adjudged to be treatable by RFA or surgical resection at an institution may not be given the same treatment at another. The best known indication criteria for surgical resection may be those proposed in the Barcelona Clinic Liver Cancer (BCLC) protocol (5), which states that surgical resection should be restricted to patients with performance status 0, Child-Pugh class A, single HCC, normal portal pressure, and normal serum bilirubin level. In patients satisfying those criteria, the 5-year survival rate is expected to be  $> 70\%$  (30). In this study, 237

(20.3%) of 1,170 patients satisfied those criteria and were thus considered good candidates for surgical resection; their 5-year survival rate was 75.9%, which appears satisfactory when compared with outcomes following surgical resection. Furthermore, in all 1,170 primary HCC patients treated by RFA, 5- and 10-year survival rates were 60.2% and 27.3%, respectively. In patients treated by surgical resection, 5- and 10-year survival rates were 34.4–70.0% and 10.5–52.0%, respectively (32,39–45). Although this is an observational study with no control, survivals following RFA appear comparable to those reported following surgical resection.

Two recent randomized controlled trials showed no significant difference in survival between RFA and surgical resection (46,47). Several nonrandomized controlled trials reported that RFA had similar overall survival rates to resection (48–50), while others found resection to be associated with higher survival rates (51–53). Further studies are necessary to resolve comparison of RFA with resection.

We have made strenuous efforts to standardize the RFA procedure. Although many physicians have participated in RFA at our institution, the procedure was invariably performed according to the institutional protocol and in the presence of experienced physicians. Video recording was also used to monitor the procedure. Additionally, preoperative planning and postoperative evaluation of technique effectiveness were also carried out by at least three physicians. We also believe that not only proficient practice of RFA but also detailed preoperative planning, cautious postoperative evaluation of therapeutic effect, and careful follow-up are vital to achieve satisfactory outcomes.

Source population in this study may represent selection bias, as we performed RFA on most patients who were hospitalized at our department; however, many patients with unfavorable tumor conditions for RFA might not have been referred to us. Therefore, caution is required when extrapolating our findings to the general population of HCC patients.

A second limitation is that study population cannot be clearly defined. This study was based on daily clinical practice over a 10-year period. Indication criteria of RFA have changed over time, mainly because another percutaneous ablation, that is, ethanol injection has also been performed. Furthermore, various treatments besides percutaneous ablation were available for HCC, such as surgical resection and transarterial chemoembolization, with frequently overlapping indications.

One further limitation is the fact that this was a single-center study; these results might not be reproducible consistently in other settings. To extrapolate the findings in this study to patients at other institutions, careful consideration should be given to differences in the indications, methods, expertise, performance of available ultrasound and CT equipment, and others. Treatment outcome may be influenced by the physicians' expertise and the institution's volume of care. We started ethanol injection in 1985 and microwave ablation in 1995, that is, before the introduction of RFA. Recently, we have performed over 900 RFA treatments per year, which may represent a far greater number of treatments than those in most other institutions. We would not recommend any change in daily clinical practice solely on the strength of our study findings.

In conclusion, our 10-year clinical experience shows that RFA could be locally curative, resulting in survival for as long as 10 years, and was a safe procedure. RFA might be a first-line treatment for selected patients with early-stage HCC.

#### CONFLICT OF INTEREST

**Guarantor of the article:** Shuichiro Shiina, MD, PhD.

**Specific author contributions:** Study concept and design, analysis and interpretation of data, and drafting of the manuscript: Shuichiro Shiina; analysis and interpretation of data and statistical analysis: Ryosuke Tateishi; study execution and data acquisition: Toru Arano, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Yoshinari Asaoka, Takahisa Sato, Ryota Masuzaki, Yuji Kondo, and Tadashi Goto; revised the article critically for important intellectual content: Haruhiko Yoshida; Masao Omata, and Kazuhiko Koike. All authors have read and approved the submitted manuscript.

**Financial support:** This study was partly supported by Health Sciences Research Grants of The Ministry of Health, Labor and Welfare of Japan (Research on Hepatitis).

**Potential competing interests:** None.

#### Study Highlights

##### WHAT IS CURRENT KNOWLEDGE

- ✓ Radiofrequency ablation (RFA) has been widely performed for hepatocellular carcinoma (HCC).
- ✓ RFA has a more reliable local antitumor effect and higher survival than ethanol injection.
- ✓ There has been no report on 10-year outcome of RFA.

##### WHAT IS NEW HERE

- ✓ Five- and 10-year survival rates in 1,170 patients with primary hepatocellular carcinoma (HCC) were 60.2 and 27.3%, respectively.
- ✓ Age, antibody to hepatitis C virus, Child-Pugh class, tumor size, tumor number, serum des- $\gamma$ -carboxy-prothrombin level, and serum lectin-reactive  $\alpha$ -fetoprotein level were significantly related to survival.
- ✓ Five- and 10-year local tumor progression rates were both 3.2%. Five- and 10-year distant recurrence rates were 74.8 and 80.8%, respectively.

#### REFERENCES

1. Parkin DM, Bray F, Ferlay J *et al*. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001;94:153–6.
2. Borie F, Bouvier AM, Herrero A *et al*. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. *J Surg Oncol* 2008;98:505–9.
3. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. *Gut* 2003;52 (Suppl 3): iii1–8.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003;362:1907–17.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208–36.
6. Shiina S, Teratani T, Obi S *et al*. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastroenterology* 2005;129:122–30.
7. Lin SM, Lin CJ, Lin CC *et al*. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma  $\leq$ 4 cm. *Gastroenterology* 2004;127:1714–23.

8. Lin SM, Lin CJ, Lin CC *et al*. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* 2005;54:1151-6.
9. Lencioni RA, Allgaier HP, Cioni D *et al*. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *Radiology* 2003;228:235-40.
10. Shiina S, Teratani T, Obi S *et al*. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. *Oncology* 2002;62 (Suppl 1): 64-8.
11. N'Kontchou G, Mahamoudi A, Aout M *et al*. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. *Hepatology* 2009;50:1475-83.
12. Tateishi R, Shiina S, Teratani T *et al*. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. *Cancer* 2005;103:1201-9.
13. Lencioni R, Cioni D, Crocetti L *et al*. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. *Radiology* 2005;234:961-7.
14. Choi D, Lim HK, Rhim H *et al*. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. *Eur Radiol* 2007;17:684-92.
15. Livraghi T, Meloni F, Di Stasi M *et al*. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? *Hepatology* 2008;47:82-9.
16. Buscarini L, Buscarini E, Di Stasi M *et al*. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. *Eur Radiol* 2001;11:914-21.
17. Raut CP, Izzo F, Marra P *et al*. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. *Ann Surg Oncol* 2005;12:616-28.
18. Teratani T, Yoshida H, Shiina S *et al*. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. *Hepatology* 2006;43:1101-8.
19. Araki T, Itai Y, Furui S *et al*. Dynamic CT densitometry of hepatic tumors. *AJR Am J Roentgenol* 1980;135:1037-43.
20. Kondo Y, Yoshida H, Tateishi R *et al*. Percutaneous radiofrequency ablation of liver cancer in the hepatic dome using the intrapleural fluid infusion technique. *Br J Surg* 2008;95:996-1004.
21. Kondo Y, Yoshida H, Shiina S *et al*. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. *Br J Surg* 2006;93:1277-82.
22. Goldberg SN, Grassi CJ, Cardella JF *et al*. Image-guided tumor ablation: standardization of terminology and reporting criteria. *Radiology* 2005;235:728-39.
23. Gaynor JJ, Feuer EJ, Tan CC *et al*. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. *J Am Stat Assoc* 1993;88:400-9.
24. Sacks D, McClenny TE, Cardella JF *et al*. Society of interventional radiology clinical practice guidelines. *J Vasc Interv Radiol* 2003;14:S199-202.
25. Sala M, Llovet JM, Vilana R *et al*. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology* 2004;40:1352-60.
26. Lencioni R, Bartolozzi C, Caramella D *et al*. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. *Cancer* 1995;76:1737-46.
27. Castellano L, Calandra M, Del Vecchio Blanco C *et al*. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. *J Hepatol* 1997;27:862-70.
28. Franco D, Capussotti L, Smadja C *et al*. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. *Gastroenterology* 1990;98:733-8.
29. Takayasu K, Arai S, Ikai I *et al*. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. *Gastroenterology* 2006;131:461-9.
30. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999;30:1434-40.
31. Minagawa M, Makuuchi M, Takayama T *et al*. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. *Ann Surg* 2003;238:703-10.
32. Poon RT, Fan ST, Lo CM *et al*. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002;235:373-82.
33. Ishii H, Okada S, Nose H *et al*. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. *Cancer* 1996;77:1792-6.
34. Mulier S, Ni Y, Jamart J *et al*. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. *Ann Surg* 2005;242:158-71.
35. Koike Y, Shiratori Y, Sato S *et al*. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. *Cancer* 2001;91:561-9.
36. Capussotti L, Muratore A, Amisano M *et al*. Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival--a European single center experience. *Eur J Surg Oncol* 2005;31:986-93.
37. Taketomi A, Kitagawa D, Itoh S *et al*. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. *J Am Coll Surg* 2007;204:580-7.
38. Imamura H, Seyama Y, Kokudo N *et al*. One thousand fifty-six hepatectomies without mortality in 8 years. *Arch Surg* 2003;138:1198-206; discussion 206.
39. Park YK, Kim BW, Wang HJ *et al*. Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis. *Transplant Proc* 2009;41:1691-7.
40. Wang CC, Iyer SG, Low JK *et al*. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. *Ann Surg Oncol* 2009;16:1832-42.
41. Kamiyama T, Nakanishi K, Yokoo H *et al*. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. *Ann Surg Oncol* 2009;16:1560-71.
42. Yamamoto J, Kosuge T, Saiura A *et al*. Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. *Jpn J Clin Oncol* 2007;37:287-95.
43. Nuzzo G, Giulianti F, Gauzolino R *et al*. Liver resections for hepatocellular carcinoma in chronic liver disease: experience in an Italian centre. *Eur J Surg Oncol* 2007;33:1014-8.
44. Hanazaki K, Kajikawa S, Shimozaawa N *et al*. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. *J Am Coll Surg* 2000;191:381-8.
45. Shimada K, Sano T, Sakamoto Y *et al*. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. *Cancer* 2005;104:1939-47.
46. Chen MS, Li JQ, Zheng Y *et al*. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006;243:321-8.
47. Lu MD, Kuang M, Liang LJ *et al*. [Surgical resection versus percutaneous ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. *Zhonghua Yi Xue Za Zhi* 2006;86:801-5.
48. Hong SN, Lee SY, Choi MS *et al*. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. *J Clin Gastroenterol* 2005;39:247-52.
49. Yamagiwa K, Shiraki K, Yamakado K *et al*. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. *J Gastroenterol Hepatol* 2008;23:482-90.
50. Yamakado K, Nakatsuka A, Takaki H *et al*. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. *Radiology* 2008;247:260-6.
51. Vivarelli M, Guglielmi A, Ruzzenente A *et al*. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. *Ann Surg* 2004;240:102-7.
52. Guglielmi A, Ruzzenente A, Valdegamberi A *et al*. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. *J Gastrointest Surg* 2008;12:192-8.
53. Abu-Hilal M, Primrose JN, Casaril A *et al*. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. *J Gastrointest Surg* 2008;12:1521-6.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

## Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times

Kenichiro Enooku · Ryosuke Tateishi · Fumihiko Kanai · Yuji Kondo · Ryota Masuzaki · Tadashi Goto · Shuichiro Shiina · Haruhiko Yoshida · Masao Omata · Kazuhiko Koike

Received: 26 March 2011 / Accepted: 1 August 2011 / Published online: 21 September 2011  
© Springer 2011

### Abstract

**Background** We evaluated the usefulness of tumor marker doubling time (DT) as an efficacy indicator of a molecular targeted anticancer agent.

**Methods** Twenty-five patients with advanced hepatocellular carcinoma (HCC) received TSU-68, a multiple tyrosine kinase inhibitor. Exponential increase in HCC-specific tumor marker levels (alpha-fetoprotein or des-gamma-carboxyprothrombin) was seen in 15 of them prior to TSU-68 administration. The relationship between tumor marker DT and tumor volume DT was evaluated. Next, tumor marker DT in the first 8 weeks of TSU-68 administration was compared with tumor marker DT before treatment. Efficacy evaluation based on changes in tumor marker DT was compared with Response Evaluation Criteria In Solid Tumors (RECIST).

**Results** Tumor marker DT and tumor volume DT were almost identical ( $r^2 = 0.94$ ,  $P < 0.001$ ) in each patient before TSU-68 administration. Efficacy evaluation based

on changes in tumor marker DT on TSU-68 administration was in accordance with RECIST in 12/15 cases. Discordance was observed in three cases, for which RECIST indicated disease progression in spite of elongated tumor marker DT. Those cases showed substantial tumor necrosis without volume shrinkage or appearance of new lesions in spite of apparent effects on target lesions.

**Conclusions** Serum tumor marker DT can be used to evaluate viable tumor burden irrespective of the presence of tumor necrosis which can compromise radiographic evaluation. This approach may be applicable to the evaluation of responses to chemotherapy, particularly to cytostatic agents (ClinicalTrials.gov number, NCT00784290).

**Keywords** Doubling time · RECIST · AFP · PIVKA-II · HCC · TSU-68

### Abbreviations

AFP	Alpha-fetoprotein
CEA	Carcinoembryonic antigen
CR	Complete response
CT	Computed tomography
DCP	Des-gamma-carboxyprothrombin
DT	Doubling time
FGFR	Fibroblast growth factor receptor
HCC	Hepatocellular carcinoma
PD	Progressive disease
PDGFR	Platelet-derived growth factor receptor
PR	Partial response
PSA	Prostate-specific antigen
RECIST	Response Evaluation Criteria In Solid Tumors
SD	Stable disease
TACE	Transcatheter arterial chemoembolization
VEGFR-2	Vascular endothelial growth factor receptor-2

K. Enooku · R. Tateishi (✉) · F. Kanai · Y. Kondo · R. Masuzaki · T. Goto · S. Shiina · H. Yoshida · M. Omata · K. Koike  
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  
e-mail: tateishi-ky@umin.ac.jp

F. Kanai  
Department of Gastroenterology,  
Chiba University Hospital, Chiba, Japan

M. Omata  
Yamanashi Prefectural Central Hospital, Kofu, Japan

## Introduction

Phase II trials of chemotherapeutic agents for solid tumors usually adopt an objective tumor response as the primary endpoint, the rationale being that the tumor response will be a surrogate for the effects of a particular agent on survival outcomes [1–4]. In evaluating a tumor response to a cancer drug, the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines are usually adopted. However, the total tumor volume thus determined is not necessarily proportional to the number of viable tumor cells, e.g., in cases of massive tumor necrosis without tumor shrinkage [5–9].

With the progress in molecular targeted cancer drugs, concerns about the appropriate design of clinical trials of such agents have emerged [10, 11]. In contrast to conventional cytotoxic agents, molecular targeted agents often show cytostatic effects, i.e., a slowing of tumor growth. The effects of such agents upon the tumor growth rate may be better evaluated not by the changes in tumor burden but by the rate of changes for which RECIST may not be particularly suitable.

Most solid malignant tumors show an exponentially increasing volume in the natural course of their growth. The tumor volume doubling time (DT) is the parameter that defines the speed of the increase. Serum levels of several tumor markers, including prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP), have been reported to correlate with tumor volume in an individual patient [12–15]. The rate of changes in tumor volume may be calculated on the basis of repeated measurements of the serum tumor marker levels. The DT of serum PSA levels has also been proposed as a biological parameter that can be used to predict the prognosis of prostate cancer, and PSA determination has now become an integral part of the disease management [16–18].

The aim of the present study was to elucidate the usefulness of tumor marker DT to evaluate the efficacy of TSU-68 against hepatocellular carcinoma (HCC). TSU-68 is an orally administered, small-molecule inhibitor of multiple receptor tyrosine kinases, vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) [19]. As a potent antiangiogenic agent, TSU-68 is expected to be effective against HCC [20], and a phase I/II study has been recently conducted in Japan [21]. In that clinical trial, the serum levels of AFP and des-gamma-carboxyprothrombin (DCP) were also scheduled to be periodically determined. Although the effect was assessed by radiologic examinations, the effect of TSU-68 may be more accurately evaluated by changes in tumor growth speed based on specific tumor marker levels [22–26].

## Methods

### Clinical trial

This study was conducted according to the ethical guidelines for epidemiologic research designed by the Ministry of Education, Culture, Sports, Science and Technology and Ministry of Health, Labour and Welfare of Japan. The study design was approved by the institutional review board of the University of Tokyo Hospital.

An open-label phase I/II trial of TSU-68 for the treatment of HCC was performed between September 2003 and February 2007 at three institutions in Japan [21]. Twenty-five of the participating patients were enrolled from the University of Tokyo Hospital. In the present study, clinical data for these 25 patients, including analyses conducted before and after the trial, were further evaluated. Briefly, histologically confirmed HCC patients without indication or response to resection, ablation, or transcatheter arterial chemoembolization (TACE) were deemed eligible. The eligibility criteria also included a World Health Organization (WHO) performance status of 2 or better, a life expectancy of not less than 90 days, and a liver function of Child–Pugh class A or B. Patients were not eligible if they had received ablation, TACE, chemotherapy, or irradiation within 4 weeks, or surgery within 6 weeks, of the commencement of the trial (washout phase).

The phase I study began with a 400 mg bid oral dose of TSU-68. Because of dose-limiting toxicities, however, this was reduced to 200 mg bid in the subsequent phase II study. At the end of each 4-week cycle, dynamic contrast-enhanced computed tomography (CT) consisting of early and late arterial, and portal venous phases was performed, and contiguous transverse sections with a thickness of 5 mm were obtained. Responses were assessed on the basis of the RECIST evaluations in predetermined target lesions. The serum levels of HCC-specific tumor markers, AFP and DCP, were scheduled to be determined every 2 weeks. TSU-68 administration was discontinued when progressive disease (PD) was observed by RECIST.

### Patients

Among the patients who had participated in the aforementioned trial, those who met the following criteria were included in the present study: (1) tumor growth prior to TSU-68 administration could be evaluated with two CT examinations performed 1–3 months before the trial and upon enrollment; (2) serum tumor marker levels could be determined at least three times during the washout phase, and a linear regression of the logarithmic transformation of marker levels over time showed an  $r^2$  greater than

0.80; and (3) TSU-68 had been administered for at least 4 weeks.

Radiological evaluation of tumor volume

Radiological evaluations were performed according to RECIST guidelines version 1.0 [27]. Not more than 10 lesions, including intrahepatic tumors and extrahepatic metastases, were selected as target lesions prior to TSU-68 administration. In addition to RECIST, we also in our present analyses estimated the volume of each target lesion as a sphere taking the average of its major and minor axes as the diameter [28], and thereby calculating the radiological tumor volume DT as

$$DT = \log(2) \times \frac{t_2 - t_1}{\log(V_2) - \log(V_1)}$$

where  $V_1$  and  $V_2$  are the volumes at times  $t_1$  and  $t_2$  [29].

Tumor markers

The HCC-specific tumor markers, AFP and DCP, were measured every 2 weeks for each patient registered in the trial. The serum AFP levels were measured via an enzyme immunoassay (ST AIA-PACK AFP, Tosoh, Tokyo, Japan) and DCP was measured using a chemiluminescent enzyme immunoassay (LUMIPULSE PIVKA-II, Eisai, Tokyo, Japan). These markers were also assayed after the termination of TSU-68 treatment, usually with a longer interval.

Tumor marker doubling time

In the present analyses, we assumed that the serum levels of tumor marker are proportional to the viable tumor volume with a fixed coefficient intrinsic to an individual case, when the tumor was producing the marker in question. Independently of the coefficient, the DT values can be calculated from two data points as

$$DT = \log(2) \times \frac{t_2 - t_1}{\log(C_2) - \log(C_1)}$$

where  $C_1$  and  $C_2$  are the serum concentrations of tumor marker at times  $t_1$  and  $t_2$ .

When data were available at more than two points, we first performed linear regression analysis of log-transformed tumor marker levels over time to determine the slope, and the DT was then calculated as

$$DT = \frac{\log(2)}{\text{slope}}$$

Note in this case that the DT becomes negative when the tumor marker levels decrease following treatment.

Tumor volume and tumor marker levels during the washout phase


The total volume of target lesions was measured via two CT examinations during the washout phase: one at 4–12 weeks before and another immediately prior to the commencement of TSU-68 treatment. The tumor volume DT was then calculated as described above. The tumor marker DT was also calculated, and the relationship between the two sets of DT values was analyzed.

Changes in the DTs during TSU-68 treatment

The serum tumor marker DT during the first 8 weeks of TSU-68 administration was similarly calculated and compared with the DT measured before the drug therapy. If TSU-68 administration had been effective, the DT should be elongated, or yield a negative value. The evaluation of drug responses based on tumor marker DT was then compared with that by the RECIST method.

Tumor marker DT after the cessation of TSU-68 treatment

When a patient was observed without any anticancer treatment for more than 4 weeks after the cessation of TSU-68 treatment and tumor marker levels were determined more than once during this period, tumor marker DTs after the cessation of TSU-68 were similarly calculated and compared with those measured at 4 weeks and immediately before the cessation of treatment. The study design we used for estimating tumor marker DT before, during, and after TSU-68 administration is summarized in Fig. 1.



**Fig. 1** Linear regression representation of the log tumor marker levels over time where  $DT = \log(2)/\text{slope}$ . The slope can be calculated using a least-squares regression or two log-transformed tumor marker values:  $DT = \log(2) \times (t_2 - t_1)/[\log(TM_2) - \log(TM_1)]$ , where  $t$  = time and  $TM$  = tumor marker level

## Results

### Patient characteristics

Among the 25 patients enrolled at the University of Tokyo Hospital, 15 met all of the inclusion criteria. The reasons for exclusion included insufficient tumor marker determination prior to TSU-68 administration (seven patients), results of CT prior to enrollment unavailable (one patient), no tumor marker elevation (one patient), and termination of TSU-68 administration at week 2 as a result of gastrointestinal bleeding (one patient). The baseline characteristics of the 15 patients included in the current study cohort are summarized in Table 1.

### Tumor volume and tumor marker prior to TSU-68 administration

The relationship between the tumor volume and tumor marker DTs is shown in Fig. 2, where each point represents data from one patient. With the least-square method, the relationship was regressed to

$$y = 1.063x - 2.941$$

where  $x$  is the tumor volume DT and  $y$  is the tumor marker DT in days for both. The slope of regression was close to 1.0 with an  $r^2$  value of 0.948, indicating that these two DTs were almost identical in each patient.

### Changes in tumor marker DT during TSU-68 treatment

TSU-68 treatment was discontinued at week 4 in four patients because of the appearance of new lesions or a substantial increase in the volume of non-target lesions. The remaining 11 patients received this drug for at least 8 weeks and the response of the target lesions was evaluated in these patients as a stable disease (SD) by RECIST at week 4. Changes in the tumor marker DT before and after the commencement of TSU-68 administration are summarized in Table 2, together with the corresponding RECIST evaluation. When the tumor marker DT was increased following TSU-68 therapy, or became negative, this was considered to be an indication of at least partial drug efficacy. On the other hand, no beneficial effects were assigned to TSU-68 when the tumor marker DT was shortened following treatment. Such tumor marker-based evaluations were found to be compatible with RECIST, as a complete or partial response (CR, PR), or SD versus PD, in 12 of 15 patients. In the remaining three patients, a RECIST-based evaluation of PD was obtained in spite of an elongated tumor marker DT. In case 9, the RECIST-based evaluation became PD after cycle 2 because of the appearance of a new lesion, although the tumor marker DT

**Table 1** Patient characteristics

Variable	<i>n</i> = 15
Age (years)	66.7 ± 6.3
Sex [no. (%)]	
Male	12 (80)
Female	3 (20)
Viral markers [no. (%)]	
HBs Ag+, HCV Ab–	2 (13)
HBs Ag–, HCV Ab+	13 (87)
Prior treatments <sup>a</sup> [no. (%)]	
TACE	13 (87)
Ablation	12 (80)
Surgery	5 (33)
Radiation	2 (13)
Systemic chemotherapy	1 (7)
Tumor stage [no. (%) <sup>b</sup> ]	
I	0 (0)
II	0 (0)
III	7 (47)
IVa	4 (27)
IVb	4 (27)
Extrahepatic metastasis [no. (%)]	8 (53)
Portal vein thrombosis [no. (%)]	1 (7)

Plus-minus values represent the mean and standard deviation

HBs Ag hepatitis B surface antigen, HCV Ab hepatitis C antibody


<sup>a</sup> Number of pretreatments by surgery, radiofrequency ablation, transcatheter arterial chemoembolization, chemotherapy, or radiotherapy

<sup>b</sup> Based on the International Union Against Cancer (UICC) *TNM Classification of Malignant Tumors*, 6th edition, 2002

was still elongated in this patient. Lymph node necrosis was observed by contrast-enhanced CT in this patient (Fig. 3), suggesting that TSU-68 remained effective. In case 10, a RECIST-based evaluation of PD was obtained because of an increase in the size of adrenal metastasis (a target lesion) although the hepatic lesions were decreased in size and the tumor marker DT was elongated. After the cessation of TSU-68 in patient 10, the left adrenal gland was excised and found to contain multiple necrotic lesions. Case 12 showed SD for the target lesion and an elongated tumor marker DT but was deemed to be a PD because of the appearance of new lesions.

In two of the other cases (nos. 1 and 2), a RECIST-based evaluation of SD was found but a negative tumor marker DT was also obtained. In case 1, the tumor marker DT became –21.1 days upon TSU-86 administration, which indicated an 84% decrease in tumor volume and 46% reduction in diameter by 8 weeks. Using RECIST parameters, a greater than 30% decrease in diameter typically corresponds to PR but case 1 was nevertheless evaluated as

SD using this system. In case 2, a tumor marker DT of –29.5 days corresponded to a decrease in diameter to 64% of baseline but the RECIST-based evaluation was SD. Importantly, necrotic lesions were found in the target tumors in both cases, possibly leading to an underestimation of anticancer effect.



**Fig. 2** Linear regression representation of the log tumor volume doubling time over the log tumor marker doubling time. Each point represents a data set from a single patient

Changes in tumor marker DT after the cessation of TSU-68 treatment

Changes in tumor marker DTs following the cessation of TSU-68 could be evaluated in four patients (Table 3). In each of these cases, the tumor marker DTs were elongated during TSU-68 administration compared with the baseline value and became shorter after the cessation of the treatment. Tumor marker DT after the cessation of TSU-68 was comparable with that before treatment in three patients and shorter in the remaining case.

Discussion

The production rate of a tumor marker per unit volume of the tumor mass can vary greatly among cancer patients who are positive for this marker. Hence, the serum levels of tumor marker are not directly proportional to the tumor volume. However, provided that the production rate per unit of tumor volume remains constant in each case, the changes in the serum tumor marker levels will directly correspond to the changes in tumor volume. Indeed, as we have shown in the present study, the DT of a tumor marker level and that of the corresponding tumor volume were almost identical in each patient in this study, at least during

**Table 2** Tumor marker doubling time and treatment response evaluated by RECIST

Case no.	Marker	Tumor marker levels <sup>a</sup>		Doubling time (days)		Treatment response by RECIST
		At enrollment	At evaluation	During washout phase	During TSU-68 administration	
1	DCP	213	29	136.8	–21.1 <sup>b</sup>	SD
2	AFP	60836	15312	38.6	–29.5 <sup>b</sup>	SD
3	DCP	5993	5007	26.9	–231.6 <sup>b</sup>	SD
4	AFP	144045	134030	75.3	–602.1 <sup>b</sup>	SD
5	AFP	12004	12010	18.8	43004	SD
6	AFP	33859	33983	24.1	3010	SD <sup>c</sup>
7	AFP	61649	88056	71.7	115.8	SD
8	AFP	198	395	51.9	60.2	SD
9	AFP	45	92	28.0	60.2	PD
10	DCP	657	997	38.1	51.0	PD <sup>c</sup>
11	DCP	3188	8275	54.7	43.6	PD
12	AFP	3404	6430	24.7	32.4	PD <sup>c</sup>
13	AFP	53	203	88.5	15.5	PD <sup>c</sup>
14	AFP	19	544	376.3	12.4	PD
15	AFP	30	169	25.7	12.0	PD <sup>c</sup>


AFP alpha-fetoprotein, DCP des-gamma carboxyprothrombin, SD stable disease, PD progressive disease

<sup>a</sup> Unit of AFP is ng/ml and unit of DCP is mAu/ml

<sup>b</sup> Became negative when the tumor marker levels decreased following treatment; negative DT values correspond to the half-life

<sup>c</sup> Calculated using the values obtained at week 4 as treatment was discontinued at this time point. The treatment response evaluations using RECIST were also performed at week 4

**Fig. 3** A case in which a RECIST evaluation of PD was obtained even though the tumor marker levels had decreased. The lymph nodes around the hepatic arteries (target lesions, arrows) in this patient were enlarged and had become internally necrotic



**Table 3** Tumor marker doubling time (days) before, during, and after TSU-68 treatment

Case no.	During washout phase	During the first 4 weeks of administration	During the last 4 weeks of administration	After cessation of administration
3	26.9	-97.1 <sup>b</sup>	91.2	41.2
4	75.3	-79.2 <sup>b</sup>	188.1	17.8
6 <sup>a</sup>	24.1	3010	-	46.3
9	28.0	60.2	60.2	35.4

<sup>a</sup> Treatment was discontinued at week 4

<sup>b</sup> Became negative when the tumor marker levels decreased following treatment

washout phase prior to TSU-68 therapy. This indicates the possibility that tumor growth rates and any changes in them can be evaluated using tumor marker DT.

To validate the usefulness of tumor marker DTs for evaluating treatment responses, we compared this approach with the RECIST guidelines during TSU-68 administration. These two methods showed comparable results in most cases (12/15) and discrepancies were due to substantial tumor necrosis without volume shrinkage or to the appearance of new lesions in spite of the sustained effects of the drug on the target lesions. Tumor marker levels can be considered to represent viable tumor burden irrespective of the presence of necrosis or fibrosis. Evaluations based on tumor marker DTs may thus provide a better assessment of the efficacy of chemotherapeutic agents. Modified RECIST was proposed after the protocol of this study was completed. In modified RECIST, only areas with hyperattenuation were measured, excluding necrotic tissues. Modified RECIST was reported to be more useful than conventional RECIST in the evaluation of antiangiogenic agents. Although we did not directly compare tumor DT with modified RECIST in the present study, assessment based on tumor DT may be closer to modified RECIST than to conventional RECIST.

In several previous papers, early changes in AFP levels were used to assess responses to HCC treatments [30–32]. However, they evaluated only initial responses to therapy. In contrast, by evaluating tumor DT based on tumor marker levels, the effectiveness of a therapeutic agent can be monitored during its administration even when it changes over time.

In previous phase III trials of sorafenib, the response rate was not high but the overall survival was significantly improved [33, 34]. Slowing down the progression of a tumor, even if there is no reduction in the tumor volume, can therefore lead to prolonged survival. In the present study, the tumor marker DT was shortened after the cessation of TSU-68 treatment in four patients, i.e., tumor growth was accelerated, indicating that TSU-68 still inhibited tumor growth. Using RECIST evaluation, however, the treatment response in such cases will be judged as a PD, because this method does not consider time. Hence, in evaluating the response to cytostatic agents in particular, such as sorafenib and TSU-68, determination of the changes in the tumor growth rate may be substantially more adequate. Tumor marker levels can be easily measured repeatedly and, as shown in the current analysis, the corresponding DTs can thus be reliably calculated. Theoretically, the serum half-life of a tumor marker may affect the calculation of tumor DT. However, the half-life of AFP is 5 days and that of DCP is 40 h, which are much shorter than the tumor halving time even when TSU-68 is effective, and are negligible in calculations.

Another application of tumor marker DTs is the estimation of tumor growth rates when the lesions are untreated. DTs may correlate with the malignant potential of the tumor. We have shown that tumor marker DTs remained similar before the administration and after the cessation of TSU-68, which may be a characteristic of cytostatic agents in contrast to cytotoxic agents [35–37]. The decision to continue cytotoxic agents that only slow down tumor growth could be partially based on the tumor marker DT prior to treatment.

There are several limitations to the use of tumor marker DTs in the evaluation of cancer drug treatment responses. First, DTs cannot be calculated when a tumor does not produce tumor markers. Second, a tumor marker profile may change during treatment, possibly as a result of somatic mutation and clonal selection in the tumor cell population. This may make interpretation of changes in DTs difficult. Lastly, whether an elongated but still positive DT is associated with improved prognosis has yet to be confirmed. In the natural course of HCC, the tumor volume DT has been reported to be associated with prognosis [38]. We thus speculate that a treatment associated with elongation of tumor marker DT can be continued if there are no alternative treatments and the side effects are tolerable.

In conclusion, we have shown that serum tumor marker levels can be used to evaluate viable tumor burden irrespective of the presence of tumor necrosis that can compromise radiographic evaluations. This may be particularly useful in the evaluation of cytostatic agents.

**Conflict of interest** The authors declare that they have no conflict of interest.

## References

- Cannistra SA. Phase II trials in *Journal of Clinical Oncology*. *J Clin Oncol*. 2009;27:3073–6.
- Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. *Eur J Cancer*. 1997;33:2326–32.
- Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. *Lancet*. 2000;356:373–8.
- Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. *Clin Cancer Res*. 2005;11:5928–34.
- Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. *AJR Am J Roentgenol*. 2007;188:768–75.
- Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. *AJR Am J Roentgenol*. 2007;188:776–83.
- Burton A. REGIST: right time to renovate? *Eur J Cancer*. 2007;43:1642.
- Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of cancer clinical trials. *Eur J Cancer*. 2006;42:1322–30.
- Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. *Eur J Cancer*. 2006;42:1031–9.
- Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). *Eur J Cancer*. 2003;39:2012–20.
- Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. *J Nucl Med*. 2004;45:357–65.
- D'Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, et al. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. *Cancer*. 1998;83:2172–80.
- Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. *Gastroenterology*. 1985;89:259–66.
- Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. *Ann Surg*. 1992;215:350–5.
- Tanaka K, Noura S, Ohue M, Seki Y, Yamada T, Miyashiro I, et al. Doubling time of carcinoembryonic antigen is a significant prognostic factor after the surgical resection of locally recurrent rectal cancer. *Dig Surg*. 2008;25:319–24.
- Stamey TA, Kabalin JN, Ferrari M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. *J Urol*. 1989;141:1084–7.
- Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. *J Urol*. 1989;141:1088–90.
- Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. *J Urol*. 1989;141:1076–83.
- Fabbro D, Manley PW. Su-6668. SUGEN. *Curr Opin Investig Drugs*. 2001;2:1142–8.
- Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. *Oncology*. 2007;72(Suppl 1):30–44.
- Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. *Cancer Chemother Pharmacol*. 2011;67:315–24.
- Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16–19 June 1998. *Ann Oncol*. 1998;9:1047–52.
- Eisenhauer EA. Response evaluation: beyond RECIST. *Ann Oncol*. 2007;18 Suppl 9:ix29–32.
- Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? *J Natl Cancer Inst*. 1999;91:1281–7.
- Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? *J Clin Oncol*. 2001;19:265–72.
- Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. *J Clin Oncol*. 2004;22:4442–5.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*. 2000;92:205–16.
- Dachman AH, MacEaney PM, Adedipe A, Carlin M, Schumm LP. Tumor size on computed tomography scans: is one measurement enough? *Cancer*. 2001;91:555–60.

29. Schwartz M. A biomathematical approach to clinical tumor growth. *Cancer*. 1961;14:1272–94.
30. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. *J Clin Oncol*. 2009;27:446–52.
31. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. *J Clin Oncol*. 2009;27:5734–42.
32. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. *Cancer*. 2010;116:4590–6.
33. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359:378–90.
34. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009;10:25–34.
35. Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. *Laryngoscope*. 1994;104:468–72.
36. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. *Lancet Oncol*. 2000;1:86–93.
37. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. *Nat Rev Cancer*. 2005;5:516–25.
38. Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. *Cancer*. 1989;63:2207–10.

This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License ([www.karger.com/OA-license](http://www.karger.com/OA-license)), applicable to the online version of the article only. Distribution for non-commercial purposes only.

## IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal

Kazuya Okushin<sup>a</sup> Yoshinari Asaoka<sup>a</sup> Izumi Fukuda<sup>b</sup>  
Naoto Fujiwara<sup>a</sup> Tatsuya Minami<sup>a</sup> Masaya Sato<sup>a</sup>  
Shintaro Mikami<sup>a</sup> Koji Uchino<sup>a</sup> Kenichiro Enooku<sup>a</sup>  
Yuji Kondo<sup>a</sup> Ryosuke Tateishi<sup>a</sup> Tadashi Goto<sup>a</sup>  
Shuichiro Shiina<sup>a</sup> Haruhiko Yoshida<sup>a</sup> Kazuhiko Koike<sup>a</sup>

<sup>a</sup>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, and <sup>b</sup>Department of Medicine II, Tokyo Women's Medical University, Tokyo, Japan

### Key Words

IGF-II · Hepatocellular carcinoma · Sorafenib · Metabolic complications · Molecular targeting therapy · IGF signal · Hypoglycemia

### Abstract

Hypoglycemia is a rare paraneoplastic manifestation of patients with neoplasms. Hypoglycemia can be induced by several causes, including an aberrant increase of hypoglycemic agents and adrenal insufficiency. Sorafenib is the first agent to demonstrate a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC). This small molecule inhibits serine/threonine kinase RAF in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature and decreases tumor growth and angiogenesis. In this paper, we report a case of HCC who was treated with sorafenib and showed severe hypoglycemia. This hypoglycemia might be induced by two causes, both adrenal insufficiency as an adverse effect of sorafenib and activation of the insulin-like growth factor (IGF) signal by excessive secretion of incompletely processed precursors of IGF-II. Although the IGF signal is suggested to be involved in aberrant growth of HCC in some cases, there is no other report showing the influence of sorafenib on HCC with active IGF signal. Unfortunately, the effect of sorafenib was limited in the present case. However, emerging drugs that directly inhibit the IGF signal can be expected to be highly effective in the treatment of HCC with hypoglycemia.

Kazuya Okushin

Department of Gastroenterology, Graduate School of Medicine  
The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku  
Tokyo 113-8655 (Japan)  
E-Mail [koxin-ty@umin.org](mailto:koxin-ty@umin.org)

## Introduction

Hypoglycemia is a rare but well-known paraneoplastic manifestation of patients with neoplasms, including hepatocellular carcinoma (HCC), which is referred to as non-islet cell tumor-induced hypoglycemia (NICTH) [1]. Excessive secretion of incompletely processed precursors of insulin-like growth factor-II (termed the 'big' IGF-II) has been suggested to cause NICTH. The IGF signal is involved in both glucose metabolism and cellular proliferation [2]. The 'big' IGF-II excessively stimulates both IGF-I and the insulin receptor, inducing hypoglycemia and tumor growth. In the era of molecular-targeted therapy, agents targeting the IGF signal are being developed to treat lung and pancreatic cancers [3]. Although this signal is suggested to be involved in aberrant growth of HCC [4], clinical trials using these agents against HCC have been initiated only recently.

Sorafenib is the first agent to demonstrate a survival benefit in the treatment of advanced HCC [5]. This small molecule inhibits serine/threonine kinase RAF in tumor cells and tyrosine kinases vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR) in the tumor vasculature, decreasing tumor growth and angiogenesis.

In this paper, we report a case of HCC that showed severe hypoglycemia and was treated with sorafenib. Since RAF is one of the downstream components of the IGF signal, sorafenib may be effective against tumors with an activated IGF signal. Although the effect was limited in the present case, emerging drugs that directly inhibit the IGF signal can be expected to be highly effective in the treatment of HCC with NICTH.

## Case Report

A 77-year-old male patient with HCC was referred to the authors' hospital. As he had no previous episodes of liver disorders, no imaging procedures had been performed. In February 2010, he was first admitted to another hospital due to bleeding gastric ulcers induced by non-steroidal anti-inflammatory drugs. During hospitalization, an abdominal CT scan showed multiple liver tumors and multiple lung nodules (fig. 1a, b). Based on elevated serum AFP (897 ng/ml) and typical CT scan images as HCC, he was diagnosed as advanced HCC and referred to our hospital in March 2010.

Administration of sorafenib was initiated at a dosage of 800 mg b.i.d. On day 7, pleural effusion was detected and his serum potassium concentration was elevated to 5.5 mEq/l. His general condition declined and he was unable to stand by day 11. On day 14, he was hospitalized because of hyperpotassemia (6.7 mEq/l) and hypoglycemia (27 mg/dl). Hyperpotassemia improved by the administration of an intravenous drip infusion of glucose and furosemide, but hypoglycemia continued at a level of 40 mg/dl. Although the basal levels of adrenal hormones were normal, ACTH and cortisol did not increase at the time of hypoglycemia. This suggested that the relative adrenal insufficiency exerted some influence on the hypoglycemia. We started to administer a short-acting corticosteroid (hydrocortone), and the blood glucose level increased rapidly to around 150 mg/dl.

However, several days later, the patient's morning fasting blood glucose level decreased to around 20 mg/dl. We administered a longer-acting corticosteroid and the patient also began to have late evening snacks. Although a sufficient amount of cortisol (prednisolone 10 mg/day) was administered, his hypoglycemia continued. We suspected that other factors were involved in the hypoglycemia, but the serum levels of insulin and IGF-I were lower than the normal limits. We assayed the patient's serum using immunoblotting with an anti-IGF-II antibody. The 'big' IGF-II was detected in the serum (fig. 2, lane 2) similarly to the serum of a patient with NICTH (lane 4). Only mature IGF-II was detected in the serum of the normal control (lane 3). Lane 1 was recombinant IGF-II.

By day 14 of sorafenib administration, though the number of lung metastases had increased (fig. 1d), the size of the liver tumors had not changed (fig. 1c) and the tumor marker levels had decreased (AFP from 4,112 to 2,381 ng/ml and PIVKA-II from 4,645 to 952 mAU/ml) (fig. 3). We concluded that sorafenib was effective. The dose of sorafenib was decreased to half (400 mg b.i.d.), and the patient was discharged. Ten days later, he was hospitalized because of unconsciousness caused by hypoglycemia. Though the hypoglycemia improved with treatments, sadly the patient died 6 days later of respiratory failure due to advanced lung metastases.

## Discussion

We treated a case of IGF-II producing HCC with sorafenib. Several previous reports have shown NICTH as a rare paraneoplastic manifestation of advanced HCC with a poor prognosis [6]. As far as we are aware, there are no reports describing HCC with NICTH treated with this novel molecular targeted agent, sorafenib. The present case showed interesting endocrine abnormalities such as hypoglycemia and hyperpotassemia due to relative adrenal insufficiency. The possibility that sorafenib suppressed adrenal function must be considered, since there were no other factors known to affect adrenal function such as metastasis to the adrenal glands. No reports have been identified that describe adrenal insufficiency due to sorafenib, while the drug is reported to affect thyroid functions. The possibility that sorafenib played a role in adrenal insufficiency is also supported by the fact that there are some reports of adrenal dysfunction caused by a similar molecular agent, sunitinib, targeting VEGFR/PDGFR [7].

The IGF signal is related to cell proliferation and tumor growth of HCC through the IGF-I receptor [4]. Kaseb et al. [8] reported that lower plasma IGF-I levels are correlated with advanced HCC and poor overall survival. Reactivation of IGF-II, including the 'big' IGF-II, is one of the most frequent mechanisms of IGF signal activation in HCC. Expression of IGF-I may be suppressed by a negative feedback of IGF-II overexpression, resulting in lower plasma IGF-I levels.

The 'big' IGF-II is suggested to induce hypoglycemia through IGF-I and the insulin receptor. Usually, hypoglycemia due to the 'big' IGF-II is not controllable with continuous infusion of glucose. Reduction of tumor volume by surgical operation [9], transarterial chemoembolization or systemic chemotherapy [1] is sometimes effective. Palliative treatments, including administration of hyperglycemic hormones such as corticosteroids and growth hormones, are performed, but the effects are transient and limited.


When the IGF-I receptor is stimulated, the downstream signaling pathways, including PI3K-AKT-TOR and RAF-MEK-ERK, are activated [2]. Sorafenib inhibits the activation of RAF. However, the efficacy of sorafenib was limited in the present case (fig. 3). Several drugs that target the IGF signal are under development [3]. Such drugs directly inhibit intracellular kinase activities or block the binding of IGF to the receptors. We suggest that these agents will likely be effective in NICTH cases. In particular, use of antibodies against IGF-II will probably be selective and safe in such cases.

### Acknowledgements

This work was supported in part by Health Sciences Research Grants of The Ministry of Health, Labor and Welfare of Japan (Research on Hepatitis).

### Disclosure Statement

The authors have no competing interests to disclose.



**Fig. 1.** CT scan images before and after the administration of sorafenib. **a, b** Images before therapy. **c, d** Images after therapy. By the administration of sorafenib, the size of the liver tumors had not changed (**a** to **c**), but the number of lung metastases had increased (**b** to **d**).